Abstract 2347P
Background
Many survivors of first primary cancers (FPCs) are at risk of developing a second primary cancer (SPC), the development of which usually leads to a worse prognosis. The development of SPCs may be closely related to the FPC. Different primary cancers have differentially high frequencies of specific SPC development. Our aim was to explore the possible correlation between the SPCs and FPCs.
Methods
We retrospectively searched and screened relevant literature on SPCs from four databases, namely, PubMed, EMBASE, Web of Science, and PMC. We also collected data on 28 different organ sites and the number of patients with SPC from The Surveillance, Epidemiology, and End Results (SEER) 8 Registry Database and NHANES database.
Results
A total of 9,617,643 patients with a FPC and 677,430 patients with a SPC were included in this meta-analysis. Patients with first primary gynaecological cancer and thyroid cancer developed second primary breast cancer and colorectal cancer more frequently. Patients with first primary head and neck cancer, anal cancer and esophageal cancer developed second primary lung cancer more frequently. Patients with first primary bladder cancer and penile cancer developed second primary lung cancer and prostate cancer more frequently. Patients with second primary bladder cancer accounted for 56% of first primary ureteral cancer patients with SPCs.
Conclusions
We recommend close clinical follow-up, monitoring and appropriate interventions in patients with relevant FPCs for better screening and early diagnosis of SPCs to prolong patient survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Peng Luo.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2222P - Frequent TERT gains in metastatic papillary thyroid carcinoma
Presenter: Sara Gil
Session: Poster session 16
2223P - Next-generation sequencing enables identification of RET rearrangements in papillary thyroid cancer
Presenter: Sergi Clavé
Session: Poster session 16
2224P - Identifying prognostic factors in patients with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) treated with tyrosine kinase inhibitors (TKI): Data from REGETNE registry
Presenter: Maria Victoria San Roman Gil
Session: Poster session 16
2225P - FOX1 (rs965513), NKX2-1 (rs944289) and BRAF (V600E) gene mutations and their role in development of papillary thyroid cancer
Presenter: Darko Katalinic
Session: Poster session 16
2226P - Survival benefit of radioiodine therapy (RAI) in papillary thyroid cancer variants (PTCV): A SEER analysis
Presenter: Sakhr Alshwayyat
Session: Poster session 16
2227P - The efficacy and safety of lenvatinib in neoadjuvant therapy in patients with locally advanced thyroid cancer: A single-arm phase II clinical trial
Presenter: Jianhong Yu
Session: Poster session 16
2228P - Long-term clinical outcomes of Lenvatinib in patients with differentiated thyroid cancer: Results from the real-world practice of a single institution
Presenter: Ryutaro Onaga
Session: Poster session 16
2229P - Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001
Presenter: Lori Wirth
Session: Poster session 16
2323P - Multi-omic spatial phenotyping of the NSCLC tumour microenvironment for the development of a spatial score associated with immunotherapy resistance
Presenter: Arutha Kulasinghe
Session: Poster session 16
2324P - Trametinib and PD-1 combined blockade impairs tumor growth and improves survival of KRAS-mutant lung cancer through Id1 downregulation
Presenter: Ander Puyalto
Session: Poster session 16